Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bluejay Diagnostics (BJDX) reported third-quarter results and completed enrollment in its SYMON-II study, exceeding the original target of 750 patients. Preliminary baseline analysis of 777 evaluable patients identified 140 deaths within 28 days, approximately 18% mortality; these data do not establish the test's prognostic performance.
Bluejay established an alternative cartridge manufacturing site through Sanyoseiko ahead of its contractual deadline and advanced U.S. manufacturing through ALURIS Sciences. It signed a distribution agreement with Lovell Government Services. Cash was $7.38 million at September 30, 2026, versus $5.16 million at December 31, 2025; nine-month operating cash use was approximately $5.09 million. Bluejay estimates cash will support operations through the second quarter of 2027, with further financing required. It plans an FDA 510(k) submission in the first half of 2027, subject to successful validation.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointCash increased to $7.38 million at September 30, 2026, from $5.16 million at December 31, 2025.
- Moderate pointSYMON-II enrollment completed, exceeding the original target of 750 patients.
- Moderate point. Forward-looking: it has not happened yet and may not happen.FDA 510(k) submission planned for the first half of 2027 for Symphony IL-6.
- Minor pointSanyoseiko alternative cartridge manufacturing site established ahead of the October 23, 2026 contractual deadline under the Toray agreement.
- Minor pointU.S. manufacturing capabilities advanced through ALURIS Sciences, supporting cartridge production, quality activities, packaging and distribution.
- Minor pointLovell Government Services distribution agreement signed to support potential access to U.S. government healthcare markets.
Negative
- Moderate point. Forward-looking: it has not happened yet and may not happen.Additional financing required for longer-term plans; Bluejay estimates existing cash supports operations through the second quarter of 2027.
- Moderate pointOperating cash use was approximately $5.09 million for the nine months ended September 30, 2026.
- Moderate pointBaseline clinical data do not establish prognostic performance or clinical utility; conclusions depend on completing planned analyses.
- Minor point. Forward-looking: it has not happened yet and may not happen.Planned FDA submission depends on successful validation; final analytical testing will follow cartridge verification and validation.
Key Figures
- Evaluable patients
- 777 patients
- SYMON-II preliminary baseline analysis
- Deaths within 28 days
- 140 deaths
- Among the 777 evaluable patients
- Mortality
- Approximately 18%
- Within 28 days in the preliminary baseline analysis
- Planned FDA 510(k) submission
- First half of 2027
- Subject to successful validation
- Cash and cash equivalents
- $7.38 million
- As of September 30, 2026
- Net cash used in operating activities
- Approximately $5.09 million
- Nine months ended September 30, 2026
- Estimated cash runway
- Through the second quarter of 2027
- Based on current operating plans
- Additional financing
- Will be required
- To support longer-term development and commercialization plans
Previous Earnings Reports
-
SYMON-II reached its 750-patient enrollment target; cash runway was estimated through Q2 2027.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
il-6 medical
510(k) regulatory
specificity medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
ACTON, MA / ACCESS Newswire / November 12, 2026 / Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing rapid, near-patient testing solutions for critical care, today reported financial results for the quarter ended September 30, 2026, and provided an update on its clinical, regulatory and manufacturing progress for the Symphony™ platform.
During the quarter and subsequent weeks, Bluejay achieved several important milestones, including completion of enrollment in its SYMON-II clinical validation study, establishment of an alternative manufacturing facility ahead of a contractual deadline, and continued advancement of its U.S. manufacturing and commercialization infrastructure.
"The third quarter marked significant progress for Bluejay as we advanced several critical elements toward regulatory submission and commercialization," said Neil Dey, President and Chief Executive Officer. "With SYMON-II enrollment completed, important manufacturing milestones achieved, and U.S. supply chain infrastructure enhanced, I believe that we have meaningfully reduced several key development and operational risks. Going forward, our focus remains on completing clinical and analytical validation and preparing for company's planned FDA submission in the first half of 2027."
Third Quarter and Recent Business Highlights
Clinical Development and Regulatory Progress
- Successfully completed SYMON-II clinical study enrollment, exceeding the original target of 750 patients.
- Preliminary baseline analysis of 777 evaluable patients identified 140 deaths within 28 days, representing approximately
18% mortality, providing a substantial clinical dataset for evaluating IL-6 prognostic performance. - Initiated preliminary sample testing and patient data analysis, with final analytical testing to follow cartridge verification and validation.
- Continued advancing toward a planned FDA 510(k) submission for Symphony IL-6 during the first half of 2027, subject to successful validation.
Manufacturing and Commercial Readiness
- Established an alternative Symphony cartridge manufacturing site through Sanyoseiko ahead of the October 23, 2026 contractual deadline under the Company's agreement with Toray Industries.
- Advanced U.S. manufacturing capabilities through ALURIS Sciences (previously Argonaut Manufacturing), supporting cartridge production, quality activities, packaging and distribution.
- Continued developing commercial infrastructure, including a entering into a distribution agreement with Lovell Government Services to support potential access to U.S. government healthcare markets.
- Progressed an exploratory artificial intelligence initiative evaluating the potential integration of IL-6 measurements and clinical data for future sepsis risk stratification applications.
These initiatives are intended to strengthen manufacturing reliability, reduce supply chain concentration risk and support potential commercialization following regulatory authorization.
As of September 30, 2026, Bluejay had
Net cash used in operating activities for the nine months ended September 30, 2026 was approximately
Outlook
Bluejay remains focused on completing SYMON-II clinical analysis, advancing analytical validation and manufacturing qualification, and preparing its planned FDA 510(k) submission during the first half of 2027.
"Our achievements in clinical development and manufacturing have positioned us to focus on the next critical phase of execution towards commercial readiness," continued Mr. Dey. "We remain committed to disciplined capital allocation, regulatory progress and building a scalable diagnostic platform with the potential to address important unmet needs in critical care."
Potential Importance of Rapid IL-6 Information
Sepsis is a highly heterogeneous and rapidly evolving condition. Patients presenting with severe infection may follow substantially different clinical trajectories, creating a need for timely information that can help clinicians assess patient risk.
Bluejay is developing the Symphony™ Suite as a rapid quantitative biomarker assay platform. The Company's development strategy is intended to bring quantitative biomarker information closer to the patient and make results available rapidly enough to potentially complement clinical assessment and established measures of disease severity.
The Company is continuing its analysis of clinical samples and data as part of its SYMON-II pivotal study, including evaluation of IL-6 measurements and their relationship to 28-day mortality and other relevant clinical parameters. The baseline characteristics announced to date do not themselves establish the prognostic performance, clinical utility, sensitivity, specificity or regulatory acceptability of the Symphony™ IL-6 Test. Those conclusions will depend upon completion of the planned analyses.
The Symphony™ IL-6 Test has not been cleared or approved by the U.S. Food and Drug Administration ("FDA") and is not currently available for commercial clinical use in the United States.
About the SYMON Clinical Study Program:
The SYMON Clinical Study Program includes SYMON-I (clinicaltrials.gov ID NCT06181604), SYMON-II (NCT06654895), and SYMON-III (NCT07425587). SYMON-I is a pilot study to determine IL-6 levels associated with various endpoints, including, but not limited to 28-day all-cause mortality and in-hospital mortality. The SYMON-II study is the pivotal study to validate the outcomes of the SYMON-I study, which the Company plans to use to support a 510(k) application to FDA. The SYMON-III study is a pilot study to determine IL-6 levels associated with patients presenting with increasing severity of infection in the emergency department and risk of developing sepsis.
About Bluejay Diagnostics:
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony™ System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay does not yet have regulatory clearance for the Symphony™ System, and we will need to receive regulatory authorization from the U.S. Food and Drug Administration before Symphony™ can be marketed as a diagnostic product in the United States. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from 'sample-to-result' to help medical professionals make earlier and better triage/treatment decisions. More information is available at www.bluejaydx.com.
Forward-Looking Statements:
This press release contains statements that the Company believes are "forward-looking statements" within the meaning of the Private Litigation Reform Act. Forward-looking statements may be identified by words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "suggest," "will," and similar expressions. The Company has based these forward-looking statements on its current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements the Company makes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including market and other conditions and those discussed under item 1A. "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in Part II, Item 1A, "Risk Factors" in its Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2026, June 30, 2026 and September 30, 2026. You should not place undue reliance on these forward-looking statements, as they are subject to risks and uncertainties, and actual results and performance in future periods may not occur or may be materially different from any future results or performance suggested by the forward-looking statements in this release. This press release speaks as of the date indicated above. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. The Company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any future changes in the Company's expectations of results or any future change in events, except as required by law.
Investor Contact:
Neil Dey
Bluejay Diagnostics, Inc.
neil.dey@bluejaydx.com
978-631-0310
Website: www.bluejaydx.com
SOURCE: Bluejay Diagnostics
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Bluejay Diagnostics report from SYMON-II enrollment?
Bluejay completed enrollment above its original target of 750 patients. Preliminary baseline analysis covered 777 evaluable patients and identified 140 deaths within 28 days, approximately 18% mortality. These baseline findings do not establish the Symphony IL-6 Test's prognostic performance.
How long does Bluejay Diagnostics expect its cash to last?
Bluejay estimates existing cash resources will support operations through the second quarter of 2027, based on current operating plans. Cash and cash equivalents were $7.38 million at September 30, 2026. Additional financing will be required for longer-term development and commercialization plans.